Together, these results suggest that, despite improvements in expansion and persistence, PRDM1 KO alone is not sufficient to potentiate robust and sustained CAR T-cell antitumor efficacy in aggressive tumor models. This evidence concerns the gene PRDM1 and neoplasm.